Clinical Trial Detail

NCT ID NCT02941926
Title Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals

Her2-receptor negative breast cancer


Ribociclib + Letrozole + Goserelin

Age Groups: adult senior

Additional content available in CKB BOOST